Loading stock data…
Janux Therapeutics, Inc. (JANX)
$15.32+0.39 (+2.58%)
Market ClosedLast close Jun 29
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Janux Therapeutics, Inc. in the Healthcare sector is trading at $15.32 with a market capitalization of $829M. Wall Street consensus targets $37.19 (16 analysts), implying a +142.7% move over the next 12 months. The stock is currently near its 52-week low of $12.12, remaining 13.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 75 is overbought against a weak tape. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +142.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 75 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.73M | $0↓ | $10.00M | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.21M↑ | -$42.40M↓ | -$35.25M↑ | -$45.12M↓ | -$34.90M |
| Net Income | -$24.36M↑ | -$31.95M↓ | -$24.31M↑ | -$33.86M↓ | -$23.51M |
Peer Comparison
JNJUNHPFE
Fundamentals
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technolo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$828.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.16%
Volume
Today's trading volume
1.18M
Recent News
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance
By Karen Roman Akari Therapeutics, Plc (Nasdaq: AKTX) said President and CEO Abizer Gaslightwala was part of a Virtual Investor “What This Means” interview highlighting the company’s first abstract acceptance […]
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
By Karen Roman VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund. The company also applied for a Nasdaq listing under the ticker symbol “VRXA” via a combination with Voyager Acquisition Corp. (Nasdaq: VACH) […] The post VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC appeared first on ExecEdge.
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.